Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.55 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.55 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.55 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.55 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17777448 | 0.85 | MAPT (0.50) | MAPTNPC1SMN1; SMN2RAB9ATAAR1 | |
| Hydrochloric Acid SCHEMBL19371465 | 0.84 | MAPT (0.49) | MAPTNPC1SMN1; SMN2RAB9ATAAR1 | |
| SCHEMBL1999045 | 0.83 | F2 (0.59) | MAPTNPC1SMN1; SMN2RAB9AF2 | |
| SCHEMBL10895758 | 0.83 | SMN1; SMN2 (0.61) | MAPTNPC1SMN1; SMN2RAB9ATAAR1 | |
| SCHEMBL29650098 | 0.83 | MAPT (0.60) | MAPTNPC1SMN1; SMN2RAB9ATAAR1 | |
| SCHEMBL28357396 | 0.83 | MAPT (0.60) | MAPTNPC1SMN1; SMN2RAB9ATAAR1 | |
| SCHEMBL6358704 | 0.83 | MAPT (0.60) | MAPTNPC1SMN1; SMN2RAB9ATAAR1 | |
| SCHEMBL24891830 | 0.82 | KMT2A (0.64) | MAPTNPC1SMN1; SMN2RAB9AF2 | |
| SCHEMBL7913893 | 0.82 | F2 (0.57) | NPC1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7922546 | 0.82 | F2 (0.57) | NPC1F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0865434-B1 | COMPOUNDS AND THEIR USE TO TREAT INFECTIOUS DISEASES | PICOWER INST MED RES (US) | 2003-12-17 | — | — | EP | claimed |
| EP-2757093-B1 | GUANIDINOBENZOIC ACID COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-12-07 | — | — | EP | disclosed |
| WO-2014142219-A1 | GUANIDINOBENZOIC ACID ESTER COMPOUND | アステラス製薬株式会社 (JP) | 2014-09-18 | — | — | WO | disclosed |
| US-20120178739-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-8124764-B2 | Fused heterocyclyc inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20110039820-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20080064643-A1 | Myd88 Homodimerization Inhibitors | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-03-13 | — | — | US | disclosed |
| US-20080064643-A1 | Myd88 Homodimerization Inhibitors | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-03-13 | — | — | US | disclosed |
| EP-0865434-B1 | COMPOUNDS AND THEIR USE TO TREAT INFECTIOUS DISEASES | PICOWER INST MED RES (US) | 2003-12-17 | — | — | EP | disclosed |
| US-4347310-A | INCREASED PHOTOSENZITIVITY USING GUANIDINE DERIVTIVES AS SENSITIZERS; PHOTOSTABILITY; STORAGE STABILITY | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1982-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178739-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | PRKCI, PIK3CA, AKT1 | MAPT 2225/4885NPC1 2485/4885SMN1; SMN2 2957/4885 |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC7 | MAPT 2011/4885NPC1 2452/4885SMN1; SMN2 3263/4885 |
| US-20110039820-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | PRKCI, PIK3CA, AKT1 | MAPT 2225/4885NPC1 2485/4885SMN1; SMN2 2957/4885 |
| US-20080064643-A1 | Myd88 Homodimerization Inhibitors | MYD88, TLR4, TLR6 | MAPT 4322/4885NPC1 4144/4885SMN1; SMN2 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.